DE69921966D1 - Verfahren zur fermentativen herstellung von cytostatika und deren kristallformen - Google Patents

Verfahren zur fermentativen herstellung von cytostatika und deren kristallformen

Info

Publication number
DE69921966D1
DE69921966D1 DE69921966T DE69921966T DE69921966D1 DE 69921966 D1 DE69921966 D1 DE 69921966D1 DE 69921966 T DE69921966 T DE 69921966T DE 69921966 T DE69921966 T DE 69921966T DE 69921966 D1 DE69921966 D1 DE 69921966D1
Authority
DE
Germany
Prior art keywords
cytostatics
epothilones
fermentative production
crystal shapes
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69921966T
Other languages
English (en)
Other versions
DE69921966T2 (de
Inventor
Hans Hofmann
Marion Mahnke
Klaus Memmert
Frank Petersen
Thomas Schupp
Ernst Kuesters
Michael Mutz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE69921966D1 publication Critical patent/DE69921966D1/de
Application granted granted Critical
Publication of DE69921966T2 publication Critical patent/DE69921966T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
DE69921966T 1998-02-19 1999-02-17 Verfahren zur fermentativen herstellung von cytostatika und deren kristallformen Expired - Lifetime DE69921966T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CH39698 1998-02-19
CH39698 1998-02-19
CH100798 1998-05-05
CH100798 1998-05-05
PCT/EP1999/001025 WO1999042602A2 (en) 1998-02-19 1999-02-17 Fermentative preparation process for cytostatics and crystal forms thereof

Publications (2)

Publication Number Publication Date
DE69921966D1 true DE69921966D1 (de) 2004-12-23
DE69921966T2 DE69921966T2 (de) 2005-11-03

Family

ID=25684443

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69921966T Expired - Lifetime DE69921966T2 (de) 1998-02-19 1999-02-17 Verfahren zur fermentativen herstellung von cytostatika und deren kristallformen

Country Status (25)

Country Link
US (8) US6194181B1 (de)
EP (2) EP1054994B1 (de)
JP (3) JP3681109B2 (de)
KR (4) KR100595774B1 (de)
CN (2) CN1286839C (de)
AT (1) ATE282710T1 (de)
AU (1) AU746294B2 (de)
BR (1) BR9908119A (de)
CA (1) CA2318818A1 (de)
CZ (1) CZ301517B6 (de)
DE (1) DE69921966T2 (de)
DK (1) DK1054994T3 (de)
ES (1) ES2233028T3 (de)
HK (1) HK1034100A1 (de)
HU (1) HU225851B1 (de)
IL (4) IL159631A0 (de)
NO (4) NO322588B1 (de)
NZ (2) NZ506138A (de)
PL (2) PL196787B1 (de)
PT (1) PT1054994E (de)
RU (1) RU2268306C2 (de)
SI (1) SI1054994T1 (de)
SK (3) SK286517B6 (de)
TR (2) TR200002431T2 (de)
WO (1) WO1999042602A2 (de)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903348B2 (de) 1995-11-17 2008-08-27 Gesellschaft für Biotechnologische Forschung mbH (GBF) Epothilon-Derivate und deren Herstellung
JP4274583B2 (ja) * 1996-11-18 2009-06-10 ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃ，ｄ，ｅ及びｆ、製造と薬剤
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
CN100381566C (zh) 1998-11-20 2008-04-16 科森生物科学公司 产生环氧噻酮及其衍生物的重组方法和材料
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
ES2254493T3 (es) * 2000-04-28 2006-06-16 Kosan Biosciences, Inc. Produccion heterologa de policetidos.
US6998256B2 (en) 2000-04-28 2006-02-14 Kosan Biosciences, Inc. Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
IL155306A0 (en) 2000-10-13 2003-11-23 Univ Mississippi Methods for producing epothilone derivatives and analogs and epothilone derivatives and analogs produced thereby
GB0029895D0 (en) 2000-12-07 2001-01-24 Novartis Ag Organic compounds
CA2434566A1 (en) * 2001-01-25 2002-08-15 Timothy M. Malloy Parenteral formulation containing epothilone analogs
YU58203A (sh) 2001-01-25 2006-08-17 Bristol-Myers Squibb Company Postupci primene epotilonskih analoga za lečenje kancera
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
HUP0303175A2 (hu) 2001-02-20 2003-12-29 Bristol-Myers Squibb Co. Epotilonszármazékok alkalmazása makacs tumorok kezelésére alkalmas gyógyszerkészítmény előállítására
IL157128A0 (en) 2001-02-20 2004-02-08 Bristol Myers Squibb Co Pharmaceutical compositions containing epothilone derivatives
EP1383490B1 (de) * 2001-03-14 2012-04-25 Bristol-Myers Squibb Company Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
US6800653B2 (en) * 2001-06-01 2004-10-05 Bristol-Myers Squibb Compnay Epothilone derivatives
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
US20060089327A1 (en) 2002-01-14 2006-04-27 Hohneker John A Combinations comprising epothilones and anti-metabolites
TW200303202A (en) * 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
WO2003074521A1 (en) * 2002-03-01 2003-09-12 University Of Notre Dame Derivatives of epothilone b and d and synthesis thereof
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
BR0309711A (pt) * 2002-05-01 2005-02-09 Novartis Ag Método para o tratamento de doenças do câncer
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
EP1575556A2 (de) * 2002-05-20 2005-09-21 Kosan Biosciences, Inc. Verfahren zur verabreichung von epothilon d
US7008936B2 (en) * 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
DE60330407D1 (de) 2002-08-23 2010-01-14 Sloan Kettering Inst Cancer Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
KR100606016B1 (ko) * 2002-09-13 2006-07-26 삼성전자주식회사 이동 통신시스템에서 양방향 데이터 서비스 제공 방법
CA2499600C (en) * 2002-09-23 2012-08-21 Daniel Benigni Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
JP2006504743A (ja) * 2002-10-09 2006-02-09 コーザン バイオサイエンシス インコーポレイテッド 治療製剤
RU2358729C2 (ru) * 2003-10-09 2009-06-20 Козан Байосайенсиз, Инк. Терапевтические композиции
WO2005034964A1 (en) * 2003-10-09 2005-04-21 Kosan Biosciences, Inc. Therapeutic formulations
PE20110102A1 (es) 2004-04-07 2011-02-07 Novartis Ag Derivados de n-(2-oxo-2-pirrolidinil-1-il)etil-2-amino-acetamida como inhibidores de proteinas de apoptosis (iap)
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007038459A2 (en) 2005-09-27 2007-04-05 Novartis Ag Carboxyamine compounds and their use in the treatment of hdac dependent diseases
CN1312286C (zh) * 2005-10-19 2007-04-25 华南理工大学 一种利用纤维堆囊菌高效生产埃博霉素的方法
EP2022498A3 (de) 2005-11-21 2012-08-15 Novartis AG Neuroendokrin-Tumorbehandlung
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
CN101415409B (zh) 2006-04-05 2012-12-05 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
MX2008012728A (es) 2006-04-05 2008-10-14 Novartis Ag Combinaciones de agentes terapeuticos para el tratamiento de cancer.
US20090317489A1 (en) 2006-05-09 2009-12-24 Hanspeter Nick Combination Comprising an Iron Chelator and an Anti-Neoplastic Agent and Use Thereof
PE20081317A1 (es) * 2006-08-16 2008-10-28 Novartis Ag Formas de cristal de la epotilona b
EP2081933B1 (de) 2006-09-29 2011-03-23 Novartis AG Pyrazolopyrimidine als pi3k-lipidkinasehemmer
US8463852B2 (en) * 2006-10-06 2013-06-11 Oracle International Corporation Groupware portlets for integrating a portal with groupware systems
JP2010519209A (ja) 2007-02-15 2010-06-03 ノバルティス アーゲー 癌を処置するためのｌｂｈ５８９と他の治療剤の組み合わせ剤
CN101918400B (zh) * 2008-02-01 2012-08-29 浙江海正药业股份有限公司 一种分离和提纯埃博霉素的方法
WO2009118292A1 (en) 2008-03-24 2009-10-01 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors
MX2010010502A (es) 2008-03-26 2010-10-26 Novartis Ag Inhibidores de desacetilasas b a base de hidroxamato.
MX2011005667A (es) * 2008-11-28 2011-06-16 Novartis Ag Combinacion farmaceutica que comprende un inhibidor de hsp90 y un inhibidor de mtor.
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
EP2391366B1 (de) 2009-01-29 2012-11-28 Novartis AG Substituierte benzimidazole zur behandlung von astrozytomen
DK2445903T3 (da) 2009-06-26 2014-06-23 Novartis Ag 1,3-Disubstituerede imidazolidin-2-on-derivater som CYP17-inhibitorer
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011018454A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
AU2010284972A1 (en) 2009-08-20 2012-03-08 Novartis Ag Heterocyclic oxime compounds
KR20120050492A (ko) 2009-08-26 2012-05-18 노파르티스 아게 테트라-치환된 헤테로아릴 화합물 및 ｍｄｍ2 및/또는 ｍｄｍ4 조절제로서의 그의 용도
PE20121471A1 (es) 2009-11-04 2012-11-01 Novartis Ag Derivados de sulfonamida heterociclicos utiles como inhibidores de mek
JP5456908B2 (ja) 2009-12-08 2014-04-02 ノバルティス アーゲー ヘテロ環式スルホンアミド誘導体
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
EP2571525A4 (de) 2010-05-18 2016-04-27 Cerulean Pharma Inc Zusammensetzungen und verfahren zur behandlung von autoimmun- und anderen erkrankungen
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
JP6002210B2 (ja) 2011-04-28 2016-10-05 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
EP2718276A1 (de) 2011-06-09 2014-04-16 Novartis AG Heterocyclische sulfonamidderivate
EP2721008B1 (de) 2011-06-20 2015-04-29 Novartis AG Hydroxy substituierte isochinolinone als p53 (mdm2 or mdm4) inhibitoren
US8859586B2 (en) 2011-06-20 2014-10-14 Novartis Ag Cyclohexyl isoquinolinone compounds
KR20140025530A (ko) 2011-06-27 2014-03-04 노파르티스 아게 테트라히드로-피리도-피리미딘 유도체의 고체 형태 및 염
ES2691650T3 (es) 2011-09-15 2018-11-28 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
US8969341B2 (en) 2011-11-29 2015-03-03 Novartis Ag Pyrazolopyrrolidine compounds
EP2794594A1 (de) 2011-12-22 2014-10-29 Novartis AG Chinolinderivate
AP4055A (en) 2011-12-22 2017-03-07 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
CA2859867A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
KR20140107573A (ko) 2011-12-23 2014-09-04 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
KR20140107574A (ko) 2011-12-23 2014-09-04 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
MX2014007725A (es) 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
CA2859869A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
EA201492007A1 (ru) 2012-05-15 2015-03-31 Новартис Аг Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
JP6080947B2 (ja) 2012-05-15 2017-02-15 ノバルティス アーゲー Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するための化合物および組成物
PT2861579T (pt) 2012-05-15 2018-04-27 Novartis Ag Derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl
US9278981B2 (en) 2012-05-15 2016-03-08 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
EP2855483B1 (de) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinonverbindungen
BR112014031421A2 (pt) 2012-06-15 2017-06-27 Brigham & Womens Hospital Inc composições para tratamento de câncer e métodos para produção das mesmas
SG11201502452RA (en) 2012-10-02 2015-05-28 Epitherapeutics Aps Inhibitors of histone demethylases
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
CN103910742B (zh) * 2013-01-07 2016-07-13 浙江海正药业股份有限公司 一种制备埃博霉素b无定形粉末的方法
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
EP2948451B1 (de) 2013-01-22 2017-07-12 Novartis AG Substituierte purinonverbindungen
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
EA030451B1 (ru) 2013-02-27 2018-08-31 Эпитерапьютикс Апс Ингибиторы гистондеметилаз
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
CN103275098B (zh) * 2013-06-07 2015-07-08 江苏迪沃特仪器设备科技有限公司 用动态轴向压缩柱分离纯化埃博霉素的方法
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
EP3046921A4 (de) 2013-09-22 2017-02-22 Calitor Sciences, LLC Substituierte aminopyrimidinverbindungen und verfahren zur verwendung
WO2015148869A1 (en) 2014-03-28 2015-10-01 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CA2943824A1 (en) 2014-03-31 2015-10-08 Gilead Sciences, Inc. Inhibitors of histone demethylases
US10426753B2 (en) 2014-04-03 2019-10-01 Invictus Oncology Pvt. Ltd. Supramolecular combinatorial therapeutics
AU2015306662A1 (en) 2014-08-27 2017-03-09 Gilead Sciences, Inc. Compounds and methods for inhibiting histone demethylases
JP2018527362A (ja) 2015-09-11 2018-09-20 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 置換されたヘテロアリール化合物および使用方法
US10683297B2 (en) 2017-11-19 2020-06-16 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
WO2019143874A1 (en) 2018-01-20 2019-07-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
FR3087650B1 (fr) 2018-10-31 2021-01-29 Bio Even Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
HU181703B (en) 1980-05-09 1983-11-28 Chinoin Gyogyszer Es Vegyeszet Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents
US4383992A (en) 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPS58179496A (ja) 1982-04-12 1983-10-20 Takeda Chem Ind Ltd ランカシジンの改良製造法
DE3372705D1 (en) 1982-04-30 1987-09-03 Takeda Chemical Industries Ltd Pharmaceutical composition and its use
US4659696A (en) 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
HU191101B (en) 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
DE3317064A1 (de) 1983-05-10 1984-11-15 Consortium für elektrochemische Industrie GmbH, 8000 München Verfahren zur herstellung von cyclooctaamylose
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
EP0216731B1 (de) * 1985-09-13 1990-03-14 Gesellschaft für Biotechnologische Forschung mbH (GBF) Makrozyklische Antibiotika
US4920214A (en) 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
NZ224497A (en) 1987-05-18 1990-04-26 Janssen Pharmaceutica Nv Pharmaceutical composition comprising flunarizine
NZ225045A (en) 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
MY104343A (en) 1987-11-23 1994-03-31 Janssen Pharmaceutica Nv Novel pyridizinamine deravatives
WO1990012035A1 (en) 1989-04-03 1990-10-18 Janssen Pharmaceutica N.V. Regioselective substitutions in cyclodextrins
GB8910069D0 (en) 1989-05-03 1989-06-21 Janssen Pharmaceutica Nv Method of topically treating acne vulgaris
DE69033926T2 (de) 1989-11-22 2002-10-24 Janssen Pharmaceutica Nv Verwendung von Piperazin-Acetamid-Derivaten gegen Reperfusionsschaden
GB9001987D0 (en) 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
IL100856A (en) 1991-02-15 1998-03-10 Janssen Pharmaceutica Nv History of carboxyl (alkyloxyalkyl of cyclodextrins, their preparation and pharmaceutical preparations containing them
CA2061891A1 (en) 1991-03-08 1992-09-09 Robert F. Van Ginckel Flunarizine containing anti-neoplastic compositions
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE4207092A1 (de) * 1992-03-06 1993-09-16 Schott Glaswerke Endoskop
DE4207922A1 (de) 1992-03-13 1993-09-23 Pharmatech Gmbh Wasserloesliche einschlussverbindungen und verfahren zu deren herstellung
CZ286619B6 (cs) 1992-03-18 2000-05-17 Janssen Pharmaceutica N. V. Stereoisomerické formy itrakonazolu a saperkonazolu, způsob jejich výroby, jejich komplexy, způsob výroby těchto komplexů, farmaceutické přípravky a způsob jejich výroby
IL105553A (en) 1992-05-06 1998-01-04 Janssen Pharmaceutica Inc Solid dosage forms consisting of a porous network of matrix that releases a substance that dissipates rapidly in water
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5395951A (en) * 1992-11-17 1995-03-07 Council Of Scientific & Industrial Research Triterpene derivatives of azadirachtin having insect antifeedant and growth inhibitory activity and a process for extracting such compounds from the neem plant
CA2092271C (en) 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
HU213200B (en) 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
TW349870B (en) 1993-09-30 1999-01-11 Janssen Pharmaceutica Nv An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof
US5565478A (en) 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
TW438601B (en) 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
AU3846395A (en) 1994-11-07 1996-05-31 Janssen Pharmaceutica N.V. Compositions comprising carbazoles and cyclodextrins
EP0903348B2 (de) 1995-11-17 2008-08-27 Gesellschaft für Biotechnologische Forschung mbH (GBF) Epothilon-Derivate und deren Herstellung
TR199800729T2 (xx) 1995-11-23 1998-07-21 Janssen Pharmaceutica N.V. Eritmeli ekstr�zyonla haz�rlanan siklodekstrin kat� kar���mlar�.
JP3865436B2 (ja) 1996-07-11 2007-01-10 塩水港精糖株式会社 分岐シクロデキストリンの製造方法
EP0923583A1 (de) 1996-08-30 1999-06-23 Novartis AG Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
JP4274583B2 (ja) 1996-11-18 2009-06-10 ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃ，ｄ，ｅ及びｆ、製造と薬剤
WO1999001124A1 (en) * 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US7407975B2 (en) 1997-08-09 2008-08-05 Bayer Schering Pharma Ag Epothilone derivatives, method for producing same and their pharmaceutical use
US6242489B1 (en) * 1997-09-25 2001-06-05 Ecological Technologies Corporation Malodorant compositions
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
DE19826988A1 (de) 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
TR200102401T2 (tr) * 1999-02-22 2001-12-21 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) C-21 Değiştirilmiş epotilonlar.
US6291684B1 (en) * 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
GB0029895D0 (en) * 2000-12-07 2001-01-24 Novartis Ag Organic compounds
GB0230024D0 (en) * 2002-12-23 2003-01-29 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20070197611A1 (en) 2007-08-23
NO20004114D0 (no) 2000-08-17
SK288058B6 (sk) 2013-03-01
IL137691A (en) 2007-12-03
PL196787B1 (pl) 2008-01-31
JP2002504346A (ja) 2002-02-12
NO20061736L (no) 1999-08-20
NZ506138A (en) 2003-07-25
CN1535971A (zh) 2004-10-13
CN1286839C (zh) 2006-11-29
AU746294B2 (en) 2002-04-18
CN1229502C (zh) 2005-11-30
KR100595774B1 (ko) 2006-07-03
WO1999042602A2 (en) 1999-08-26
NO20004114L (no) 2000-10-17
DK1054994T3 (da) 2005-03-14
CA2318818A1 (en) 1999-08-26
SK286517B6 (sk) 2008-12-05
SI1054994T1 (en) 2005-06-30
IL137691A0 (en) 2001-10-31
EP1428826A3 (de) 2004-10-27
US20030220379A1 (en) 2003-11-27
EP1428826A2 (de) 2004-06-16
AU3028799A (en) 1999-09-06
KR20080070781A (ko) 2008-07-30
CZ20002994A3 (cs) 2000-11-15
SK287677B6 (sk) 2011-05-06
EP1054994B1 (de) 2004-11-17
US20020165256A1 (en) 2002-11-07
IL159631A0 (en) 2004-06-01
HK1034100A1 (en) 2001-10-12
US6656711B2 (en) 2003-12-02
JP2010099089A (ja) 2010-05-06
US7101702B2 (en) 2006-09-05
NO321596B1 (no) 2006-06-06
ATE282710T1 (de) 2004-12-15
US6194181B1 (en) 2001-02-27
BR9908119A (pt) 2000-10-24
HUP0100855A3 (en) 2005-05-30
KR20060032222A (ko) 2006-04-14
SK12402000A3 (sk) 2001-05-10
KR100873526B1 (ko) 2008-12-11
PL404926A1 (pl) 2013-12-09
KR20010041068A (ko) 2001-05-15
HUP0100855A2 (hu) 2001-06-28
US20090326239A1 (en) 2009-12-31
CZ301517B6 (cs) 2010-03-31
JP3681109B2 (ja) 2005-08-10
WO1999042602A3 (en) 1999-11-25
TR200002431T2 (tr) 2001-01-22
EP1054994A2 (de) 2000-11-29
HU225851B1 (en) 2007-11-28
IL159631A (en) 2007-07-04
NZ525622A (en) 2004-10-29
RU2268306C2 (ru) 2006-01-20
TR200101634T2 (tr) 2002-06-21
US20040142990A1 (en) 2004-07-22
NO20052034L (no) 2000-10-17
EP1054994A4 (de) 2001-06-19
NO329063B1 (no) 2010-08-09
PT1054994E (pt) 2005-04-29
NO322588B1 (no) 2006-10-30
KR20070058021A (ko) 2007-06-07
NO20061735L (no) 1999-08-20
US6380227B1 (en) 2002-04-30
JP2005068156A (ja) 2005-03-17
DE69921966T2 (de) 2005-11-03
PL342423A1 (en) 2001-06-04
CN1291239A (zh) 2001-04-11
ES2233028T3 (es) 2005-06-01
US20030194787A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
DE69921966D1 (de) Verfahren zur fermentativen herstellung von cytostatika und deren kristallformen
ATE426021T1 (de) Verfahren zur herstellung von biopterinen
DE69939901D1 (de) Verfahren und materialien zur herstellung von glucosamin
ATE313619T1 (de) Bioreaktor für die kultivierung von mikroorganismen sowie verfahren zur herstellung desselben
DE69329154D1 (de) Erhöhte produktion von taxol und taxanen mittels -taxus-spezifische zellkulturen
DE69637656D1 (de) Methoden zur Züchtung von Tierzellen
ATE334218T1 (de) Verfahren zur gleichzeitigen herstellung von xylitol und ethanol
DK88586D0 (da) Fremgangsmaade til fremstilling af l-carnitin ad mikrobiologisk vej
DE60129091D1 (de) Verfahren zur Herstellung eines Kulturmediums aus erneuerbarem Rohmaterial
DE60105435D1 (de) Verfahren zur herstellung von beta-karotin
ATE274597T1 (de) Verfahren zur herstellung und rückgewinnung von erythritol aus kulturmedium
DE60207914D1 (de) Verfahren zur Herstellung von L-Glutaminsäure
DE60307403D1 (de) Bakterien und Verfahren zur Herstellung von Riboflavin durch Fermentation
ATE144512T1 (de) Verfahren zur herstellung von folsäure
ATE174966T1 (de) Verfahren zur herstellung von biotin
ATE386838T1 (de) Pflanzennährlösung aus einem wiedergewonnenem filtrat aus pflanzenfaser-biopulp sowie herstellungsverfahren
ATE355359T1 (de) Selektionsmedia für beauveriolid i oder iii und verfahren zur selektiven herstellung dieser substanzen
EP0939133A3 (de) Verfahren zur Herstellung von Polyol durch Recyclisierung von Mikroorganismen
DE3884922T2 (de) Verfahren zur Herstellung von thermostabilen alpha-Amylasen durch Kultivierung von überproduzierenden Mikroorganismen.
DE60323649D1 (de) Methode zur Herstellung von Neuronen aus Stammzellen und Medium zur Kultur von Stammzellen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN